Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)

• Published in: Wiener Klinische Wochenschrift 2023-01, Vol.135 (Suppl 1), p.32
• Main Authors: Clodi, Martin, Abrahamian, Heidemarie, Brath, Helmut, Schernthaner, Guntram, Brix, Johann, Ludvik, Bernhard, Drexel, Heinz, Saely, Christoph H, Fasching, Peter, Rega-Kaun, Gersina, Föger, Bernhard, Francesconi, Claudia, Fröhlich-Reiterer, Elke, Kautzky-Willer, Alexandra, Harreiter, Jürgen, Luger, Anton, Resl, Michael, Riedl, Michaela, Winhofer, Yvonne, Hofer, Sabine E, Hoppichler, Friedrich, Huber, Joakim, Kaser, Susanne, Ress, Claudia, Lechleitner, Monika, Aberer, Felix, Mader, Julia K, Sourij, Harald, Toplak, Hermann, Paulweber, Bernhard, Stechemesser, Lars, Pieber, Thomas, Prager, Rudolf, Stingl, Harald, Stulnig, Thomas, Rami-Merhar, Birgit, Roden, Michael, Schelkshorn, Christian, Wascher, Thomas C, Weitgasser, Raimund, Zlamal-Fortunat, Sandra
• Format: Article
• Language: ger
• Subjects: Blood Glucose; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Humans; Hyperglycemia - drug therapy; Hypoglycemic Agents - therapeutic use
• ISSN: 1613-7671; 1613-7671
• DOI: 10.1007/s00508-023-02186-4

Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.